Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.
His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.